01 / DESIGN
What was studied?
A randomized phase 3 trial enrolled 475 adults whose type 2 diabetes remained inadequately controlled on insulin glargine, with or without metformin. Tirzepatide or placebo was added, and the primary outcome was HbA1c change at 40 weeks.
02 / FINDINGS
What did the researchers report?
Adding tirzepatide produced greater HbA1c reductions than adding placebo to the titrated insulin regimen. Body weight and glucose-control thresholds were also assessed, alongside adverse events and treatment discontinuation.
03 / LIMITS
How should it be interpreted?
An add-on design estimates an effect within a specified background-treatment strategy. It does not establish that a substance can replace insulin, and it is not a personal-use combination recommendation. Selected participants, monitoring and pharmaceutical formulation limit transfer to other contexts.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.